Our focus on the life sciences
We are an international life sciences investor. Our portfolio includes private and publicly held companies at all stages of development from start-ups to mature enterprises. We leverage our healthcare heritage to provide capital, know-how, and a valuable network to our portfolio companies.
Healthcare
Our teams invest across various healthcare subsectors. We focus on innovative companies developing new or improved medical therapies, or solutions to increase quality, improve efficiency or lower costs in healthcare.
Key figures
Currency
DKK
13
bn
Deployed into life sciences in 2025
300+
Life science investments since 1999
12
New companies added to our Investment Portfolio in 2025
News
06/5/2026
HST Pathways Announces Strategic Growth Investment from Novo Holdings
Read more
News
06/1/2026
Novo Holdings portfolio company Hemab Therapeutics completes successful Nasdaq IPO
Read more
News
05/26/2026
Novo Holdings announces acquisition of portfolio company LimmaTech Biologics by Lilly
Read more
News
05/4/2026
Novo Holdings joins $165 million crossover financing for Windward Bio to advance pipeline of long-acting immunology therapies with best-in-disease potential
Read more